Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study

|
By Benjamin John Cowling, Gabriel Matthew Leung
| medRxiv
Abstract Background Evidence evaluating real-world effectiveness of oral antivirals against Omicron variants is lacking. Methods An unselected, territory-wide cohort of all initially non-hospitalized patients with an officially registered diagnosis of SARS-CoV-2 infection between 26th February and 3rd May 2022 during the Omicron BA.2.2 wave in Hong Kong, was identified. We undertook a retrospective cohort design as primary analysis, and case-control design as sensitivity analysis.
Open in Who Shared Issue with article?
May 27, 2022
RT @EricTopol: 1st report of real-world effectiveness of Paxlovid in the outpatient setting, BA.2 wave, Hong Kong 75% reduced deat… https://t.co/eThMTSnY2q
May 26, 2022
RT @bhrenton: The first report of real-world effectiveness of Paxlovid in outpatients has been published as a preprint by researc… https://t.co/V4Qrn0FGWT
May 26, 2022
The first report of real-world effectiveness of Paxlovid in outpatients has been published as a preprint by researchers in Hong Kong. A course of Paxlovid helped reduce all-cause mortality by 75% and hospitalization by 31%.  https://www.medrxiv.org/content/10.1101/2022.05.26.22275631v1 …
May 26, 2022
1st report of real-world effectiveness of Paxlovid in the outpatient setting, BA.2 wave, Hong Kong 75% reduced death, 31% reduced hospitalization, 53% reduced adverse outcomes No impact of vaccination on outcomes; superior to Molnupiravar impact  https://www.medrxiv.org/content/10.1101/2022.05.26.22275631v1 … @hkumed pic.twitter.com/SMP3bC5Hip